Prospect News: News for Arena Pharmaceuticals, Inc.

E-mail us: service@prospectnews.com Or call: 212 374 2800

Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products

Add to balance / Manage account

Not logged in

Prospect News home > Main news index > All issuers starting with A > All stories on Arena Pharmaceuticals, Inc.

Search again

Enter part or all of the issuer name:

Market:

All markets No structured products Bank loans Canadian bonds CLOs Convertibles Distressed debt Emerging markets High yield Investment grade Liability management Municipals PIPEs Preferreds Private placements All leveraged markets Structured products

Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each. All others are $1.00 each. Headlines in gray are not currently covered by your subscription.

Arena Pharmaceuticals, Inc.

6/12/2019	SP	New Issue: JPMorgan sells $1 million yield notes with contingent digital return on Arena Pharmaceuticals
1/11/2012	PP	Arena to raise $33 million via sale of stock, convertible preferreds
11/8/2011	PP	Arena Pharmaceuticals negotiates $50 million stock purchase agreement
11/8/2011	CVPF	Arena files $50 million shelf covering stock, preferreds and debt
3/29/2011	PP	Arena Pharmaceuticals plans $35.48 million sale of preferreds, shares
8/6/2010	PP	New Issue: Arena Pharmaceuticals prices $60 million registered offering of stock
8/6/2010	PP	Market Commentary: Sun Communities receives $100 million line; Arena gets investment; Multiband inks equity line
6/3/2010	PP	New Issue: Arena Pharmaceuticals plans $35.53 million private placement of stock
6/3/2010	PP	Market Commentary: Prime Sun secures €51.32 million from Bangkok Solar; Arena Pharmaceuticals gets $35.5 million
5/3/2010	CVHYPF	Arena Pharmaceuticals files $150 million stock, preferreds, debt shelf
6/17/2009	BKPPPV	New Issue: Arena Pharmaceuticals seals $100 million credit facility with Deerfield
6/17/2009	PP	Market Commentary: Arena signals confidence in debt deal; BlackRock reveals pricing; Quest to sell units
3/23/2009	PP	New Issue: Arena arranges $50 million committed equity financing facility
1/26/2009	SS	OppenheimerFunds reports 8.31% stake in Arena Pharmaceuticals
6/26/2007	SP	New Issue: HSBC sells $260,000 of 17.7% reverse convertibles linked to Arena Pharmaceuticals
6/6/2007	SP	HSBC to issue 17.7% reverse convertibles linked to Arena Pharmaceuticals
10/25/2006	BT	Arena reports cash of $250.8 million at Sept. 30 thanks to follow-on stock sale
10/25/2006	BT	Market Commentary: Cadence rises after pricing below range; ImClone dips, ends up 5%; PDI off by 4%; Arena rebounds 7%
9/27/2006	BT	Arena, Ortho-McNeil extend diabetes partnership
9/25/2006	BT	Arena, Merck end atherosclerosis drug development
9/21/2006	BT	Arena: six-month analysis of phase 3 lorcaserin trial will determine feasibility of more studies
9/15/2006	BT	Market Commentary: Vertex slips but deal a hit; Barrier, Auxilium rise on PIPEs deals; ImClone, Encysive, Arena higher
9/12/2006	BT	Arena starts phase 3 trial for weight loss drug lorcaserin
8/31/2006	BT	Arena Pharmaceuticals files $148.25 million stock shelf
7/25/2006	BT	Arena second-quarter and six-month revenues up for 2006
7/6/2006	BTPP	Arena Pharmaceuticals settles dispute with Smithfield over exchange warrants
6/21/2006	BT	Market Commentary: Cell Therapeutics gains on equity financing; Arena higher on data; MedImmune airs $1 billion bond deal
6/21/2006	BT	Arena's APD125 for insomnia improves sleep in three phase 1 clinical trials
6/15/2006	BT	Arena preparing to begin phase 3 clinical trial of lorcaserin
6/13/2006	BT	Market Commentary: Lexicon drops 5%; Genitope stays steady; Vivus, Arena decline amid their respective obesity drug news
6/12/2006	BT	Patients in phase 2b trial of Arena's lorcaserin experience significant weight loss compared to placebo
5/18/2006	BT	Arena gets $4 million milestone payment from Merck
3/29/2006	BT	Arena says FDA has questions about insomnia drug APD125
3/20/2006	BTPP	Arena Pharmaceuticals preferred holder exercises call option for warrants
2/7/2006	BT	Arena, Ortho-McNeil initiate phase 1 trial for type 2 diabetes oral drug candidate
2/2/2006	BT	Arena greenshoe partly exercised, raising follow-on stock sale to $179.77 million
1/27/2006	BT	New Issue: Arena raises $164.8 million in follow-on of 9.75 million shares at $16.90
1/27/2006	BT	Market Commentary: Arena up after follow-on; Altus interest grows; Nektar, Pfizer up; Glaxo gains on Gates' TB pledge; Teva prices
1/24/2006	BT	Market Commentary: Nuvelo, Tercica toss hats in ring; Serono plunges on lack of suitors; Imclone results miss, seeks merger
1/23/2006	BT	Market Commentary: Genitope shares fall nearly 10% on follow-on plans; Arena slides; SkyePharma up; MannKind drops
1/18/2006	BT	Market Commentary: KV Pharmaceutical stock up on patent ruling; biotech offerings take a back seat to tech market
1/17/2006	BT	Arena plans follow-on of 8.5 million shares via CIBC, UBS
1/17/2006	BT	Market Commentary: Arena gains in face of follow-on deal; deCODE spikes on diabetes discovery; Acadia, Sepracor firm
12/30/2005	BT	Arena says it will advance cardiovascular agonist APD791 to preclinical studies
12/30/2005	BT	Arena obtains European patent relating to 5-HT2A agonists, which have potential use in insomnia drugs
12/13/2005	BT	Arena's ADP356 produces weight loss in phase 2a study
11/7/2005	BT	Arena Pharmaceuticals files shelf for 10 million shares

©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.